{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:13:07Z","timestamp":1783642387175,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06497-7","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T05:02:37Z","timestamp":1778994157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report"],"prefix":"10.1007","volume":"152","author":[{"given":"Xi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ErChang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"issue":"3","key":"6497_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"6497_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/medicina57080749","volume":"57","author":"J Dobruch","year":"2021","unstructured":"Dobruch J, Oszczud\u0142owski M (2021) Bladder cancer: current challenges and future directions. Medicina 57(8):749","journal-title":"Medicina"},{"key":"6497_CR3","doi-asserted-by":"publisher","first-page":"100785","DOI":"10.1016\/j.xcrm.2022.100785","volume":"3","author":"J Hu","year":"2022","unstructured":"Hu J, Chen J, Ou Z et al (2022) Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study. Cell Rep Med 3:100785","journal-title":"Cell Rep Med"},{"key":"6497_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21037\/tau-23-494","volume":"13","author":"T Lan","year":"2024","unstructured":"Lan T, Ran S, Gao M et al (2024) A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend? Transl Androl Urol 13:293\u2013307","journal-title":"Transl Androl Urol"},{"key":"6497_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s11864-025-01355-z","volume":"26","author":"L Meng","year":"2025","unstructured":"Meng L, Khorasanchi A, Jain R (2025) Advancing bladder cancer management: the role of neoadjuvant and adjuvant therapies and biomarkers in muscle invasive bladder cancer. Curr Treat Options Oncol 26:929\u2013942","journal-title":"Curr Treat Options Oncol"},{"issue":"25","key":"6497_CR6","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP et al (2023) Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol 41(25):4107\u20134117","journal-title":"J Clin Oncol"},{"key":"6497_CR16","doi-asserted-by":"publisher","unstructured":"Powles TB, Van der Heijden MS, Loriot Y, Bedke J, Valderrama BP, Iyer G, Kikuchi E, Hoffman-Censits J, Vulsteke C, Drakaki A, Rausch S, Arafat W, Park SH, Swami U, Li JR, Duran I, Gorla S, Homet Moreno B, Yu X, Lu YT, Gupta S. Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial. Ann Oncol. 2025 Oct;36(10):1212-1219. 10.1016\/j.annonc.2025.05.536. Epub 2025 Jun 1. PMID: 40460988. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.536","DOI":"10.1016\/j.annonc.2025.05.536"},{"issue":"10","key":"6497_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"3","key":"6497_CR9","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"6497_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0693-2","author":"B Tang","year":"2019","unstructured":"Tang B, Yan X, Sheng X et al (2019) Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-018-0693-2","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6497_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R et al (2021) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79(1):82\u2013104","journal-title":"Eur Urol"},{"key":"6497_CR13","doi-asserted-by":"publisher","first-page":"101216","DOI":"10.1016\/j.neo.2025.101216","volume":"68","author":"L Zhang","year":"2025","unstructured":"Zhang L, Jin D, Zang J et al (2025) Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study. Neoplasia 68:101216","journal-title":"Neoplasia"},{"key":"6497_CR12","doi-asserted-by":"publisher","first-page":"1562260","DOI":"10.3389\/fonc.2025.1562260","volume":"15","author":"R Zhang","year":"2025","unstructured":"Zhang R, Ke CX (2025) Advances in bladder preservation therapy for muscle-invasive bladder cancer. Front Oncol 15:1562260","journal-title":"Front Oncol"},{"issue":"6","key":"6497_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A et al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24(6):669\u2013681","journal-title":"Lancet Oncol"},{"key":"6497_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","volume":"53","author":"S Zsch\u00e4bitz","year":"2023","unstructured":"Zsch\u00e4bitz S, Biernath N, Hilser T et al (2023) Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real-world patient cohort. Eur Urol OPEN Sci 53:31\u201337","journal-title":"Eur Urol OPEN Sci"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06497-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:15:17Z","timestamp":1783638917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06497-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6497"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06497-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8776083\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript is a single-patient case report. According to the policy of the Ethics Committee of Affiliated Suzhou Hospital of Nanjing Medical University, standalone case reports do not require formal ethical approval. The study was conducted in accordance with the Declaration of Helsinki and institutional ethical guidelines. The Ethics Committee of Affiliated Suzhou Hospital of Nanjing Medical University has confirmed exemption from full review for this type of study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient \u2018s family for the publication of the case report and all accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"132"}}